Q2 2026 saw 3% organic growth and adjusted EPS of $1.41, both above guidance, driven by strong Diagnostics and AI-related demand in Life Sciences. Full-year outlook was raised for organic growth, margins, and EPS, with robust cash flow and a pending China Immunodiagnostics divestiture.Based on Revv…
Q2 saw 3% organic growth and adjusted EPS of $1.41, both above guidance, driven by strong diagnostics and AI-related demand. Full-year outlook was raised for organic growth, margins, and EPS, with robust backlog and new product launches positioning the company for continued momentum.Based on Revvit…
Life sciences company Revvity NYSE:RVTYwill be reporting earnings this Tuesday before the bell. Here’s what investors should know.Revvity missed analysts’ revenue expectations last quarter, reporting revenues of $686.9 million, up 9.3% year on year. It was a softer quarter for the company, with ful…
The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 13, 2026 to all shareholders of record at the close of business on October 23, 2026.About Revvity At Revvity, “impossible” is in…
Explore more price target data and ratings for Revvity, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Revvity, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not…
